Stockholders' Equity (Details) - USD ($)											12 Months Ended
Stockholders' Equity (Details) - USD ($)	Oct. 24, 2025	Aug. 14, 2025	Aug. 01, 2025	Jul. 30, 2025	Jun. 18, 2025	Jan. 27, 2025	Dec. 13, 2024	Apr. 18, 2024	Mar. 01, 2024	May 31, 2023	Dec. 31, 2025	Dec. 31, 2024	Nov. 25, 2025	Jun. 30, 2025	Jun. 17, 2025	May 02, 2025	Aug. 19, 2024
Shareholders’ Equity [Line Items]
Number of shares authorized											100,000,000	100,000,000
Net proceeds											$ 2,600,000
Common stock, value											1,111	$ 259
Newly issued shares											3,658,552	4,021,485
Weighted average price, percentage										95.00%
Total proceeds											93,044
Sold amount											4,900,000
Stock-based compensation, common stock issued for services											367,750	199,378
Escrow restricted shares	10,000
Exercise price per share									$ 2.82
Proceeds from warrant exercise, net of expenses									$ 756,732		$ 4,814,743	$ 3,824,264
Net proceeds of transaction									$ 3,100,000
Percentage of common stock shares											200.00%
Fair value per warrant											$ 51.65
Issuance per warrant											$ 48.5
Inducement expenses											$ 4,464,427
Common stock, shares issued											1,111,010	258,826
Outstanding options intrinsic value											$ 0
Weighted average fair value at issued											$ 16.7	$ 25.91
Unrecognized compensation costs											$ 575,700
Recognized over a weighted average period											1 year 10 months 24 days
Common stock warrant purchase					213,648				10,737
Additional equity issuance cost											$ 300,000				$ 197,000
Equity issuance cost											3,000,000
Offering price per share					$ 8.1275
Net proceeds from exercise of warrants and equity					$ 600,000						8,500,000
Additional paid in capital											$ 95,247,841	$ 86,063,148
Number of shares held											216,960
Net proceeds from sale of common stock											$ 3,658,552	4,021,485
Series B-1 Warrants [Member]
Shareholders’ Equity [Line Items]
Common stock warrant purchase															99,290
Series C-1 Warrants [Member]
Shareholders’ Equity [Line Items]
Common stock warrant purchase											8,924				161,000
New Warrants [Member]
Shareholders’ Equity [Line Items]
Exercise price per share											$ 23.125
Prior Warrants [Member]
Shareholders’ Equity [Line Items]
Exercise price per share															$ 8.75
Pre Funded Warrants [Member]
Shareholders’ Equity [Line Items]
Common stock warrant purchase					230,352
Offering price per share					$ 8.1025
Additional paid in capital														$ 3,300,000
Series D Warrants [Member]
Shareholders’ Equity [Line Items]
Exercise price per share											$ 10.9375
Common stock warrant purchase					444,000						4,244
Series E Warrants [Member]
Shareholders’ Equity [Line Items]
Common stock warrant purchase					333,000
Stock Warrants [Member]
Shareholders’ Equity [Line Items]
Net proceeds					$ 3,000,000						$ 2,200,000
Additional equity issuance cost											500,000
Equity issuance cost											$ 3,000,000
Warrant [Member]
Shareholders’ Equity [Line Items]
Exercise price per share											$ 8.75
Net proceeds from warrant offerings									$ 3,500,000
Excess fair value											$ 3.125
2017 Equity incentive Plan [Member]
Shareholders’ Equity [Line Items]
Number of shares issued under the plan											144,075
Common Stock [Member]
Shareholders’ Equity [Line Items]
Newly issued shares											$ 300	$ 94
Stock-based compensation, common stock issued for services (in Shares)											15,891	96
Stock-based compensation, common stock issued for services											$ 16
Net proceeds from sale of common stock (In Shares)											300,161	93,940
Common Stock [Member] \| Series C Warrants [Member]
Shareholders’ Equity [Line Items]
Exercise price per share											$ 3.125
Common stock warrant purchase											92,000
Common Stock [Member] \| Warrant [Member]
Shareholders’ Equity [Line Items]
Exercise price per share									$ 70.5
Common stock warrant purchase									46,000
Common Stock [Member] \| 2017 Equity incentive Plan [Member]
Shareholders’ Equity [Line Items]
Common stock, shares issued																	96
Other Common Stock [Member]
Shareholders’ Equity [Line Items]
Stock-based compensation, common stock issued for services (in Shares)		8,695				4,000
Cash						$ 4,970
Stock-based compensation, common stock issued for services						$ 100,000
Other Common Stock [Member] \| CFO [Member]
Shareholders’ Equity [Line Items]
Stock-based compensation, common stock issued for services		$ 100,000
Net proceeds from sale of common stock (In Shares)				3,196
Final payout for the earned bonus valued				$ 36,050
At-the-Market Offering Agreement 2025 [Member]
Shareholders’ Equity [Line Items]
Sale of stock			4,983,000								80,839
Fixed commission rate on sale of common stock			3.00%
Net proceeds											$ 531,000
At-the-Market Offering Agreement 2024 [Member]
Shareholders’ Equity [Line Items]
Fixed commission rate on sale of common stock											3.00%
Other expenses								$ 77,600
At-the-Market Offering Agreement 2024 [Member] \| Common Stock [Member]
Shareholders’ Equity [Line Items]
Sale of stock												93,940
Common stock, value								$ 4,283,650
Net proceeds from sale of common stock												$ 4,021,485
Standby Equity Purchase Agreement [Member]
Shareholders’ Equity [Line Items]
Sale of stock											5,666
Other expenses												$ 74,999
Newly issued shares							$ 5,000,000				$ 2,752
Purchase commitment, amount										$ 3,000,000
Average Daily Trading Value										2,000,000
Standby Equity Purchase Agreement [Member] \| Common Stock [Member]
Shareholders’ Equity [Line Items]
Common stock, value										500,000
Inducement Agreement [Member] \| Series B Warrants [Member]
Shareholders’ Equity [Line Items]
Common stock warrant purchase																56,737
Inducement Agreement [Member] \| Series C Warrants [Member]
Shareholders’ Equity [Line Items]
Exercise price per share																$ 18.5
Common stock warrant purchase																92,000
Inducement Agreement [Member] \| Series B-1 Warrants [Member]
Shareholders’ Equity [Line Items]
Common stock warrant purchase																99,290
Inducement Agreement [Member] \| Series C-1 Warrants [Member]
Shareholders’ Equity [Line Items]
Exercise price per share																$ 18.5
Common stock warrant purchase													161,000			161,000
Inducement Agreement [Member] \| Series E Warrants [Member]
Shareholders’ Equity [Line Items]
Exercise price per share													$ 7.75
Common stock warrant purchase													207,627
Inducement Agreement [Member] \| Series F Warrants [Member]
Shareholders’ Equity [Line Items]
Exercise price per share													$ 7.75
Common stock warrant purchase													552,940
Minimum [Member]
Shareholders’ Equity [Line Items]
Number of shares authorized			50,000,000
Minimum [Member] \| 2017 Equity incentive Plan [Member]
Shareholders’ Equity [Line Items]
Number of shares authorized for grant			80,000
Minimum [Member] \| Standby Equity Purchase Agreement [Member]
Shareholders’ Equity [Line Items]
Newly issued shares										3,000,000
Maximum [Member]
Shareholders’ Equity [Line Items]
Number of shares authorized			100,000,000
Maximum [Member] \| 2017 Equity incentive Plan [Member]
Shareholders’ Equity [Line Items]
Number of shares authorized for grant			200,000
Maximum [Member] \| Standby Equity Purchase Agreement [Member]
Shareholders’ Equity [Line Items]
Newly issued shares										$ 10,000,000

ADIAL PHARMACEUTICALS, INC. 10-K